← Back to Search

Sodium-Glucose Cotransporter-2 Inhibitor

Empagliflozin 25 mg for Epilepsy

Q: What is the total sample size for this experiment?

Affirmative. According to the clinicaltrials.gov database, recruitment for this medical study began on August 17th 2022 and is continuing until 18 participants have been enrolled at a single site.

Q: Is the upper age limit for enrolment in this research project 75 years?

Qualified applicants must be 18 years of age or older, with the upper limit for enrollment set at 45.

Q: Is it possible to enroll in this investigation?

This research is seeking 18 volunteers who experience aura and are aged between 18-45. Most crucially, the eligible candidates must have one of the following epileptic conditions: focal, generalized, combined generalized and focal or an unknown type. Additionally, the <a href="https://www.withpower.com/clinical-trials/epilepsy">epilepsy</a> should be either drug-responsive or drug resistant.

Q: Is enrollment for this trial currently open?

According to clinicaltrials.gov, this trial is actively sourcing participants. The initial post date was August 17th 2022 and the listing has since been updated on 8/20/2022.

Phase < 1

Recruiting

Led By Kwee L Thio

Research Sponsored by Washington University School of Medicine

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be between 18 and 65 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 2 weeks

Awards & highlights

Study Summary

This trial will test whether a diabetes drug can be used to treat epilepsy in adults who haven't responded to other drugs.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 2 weeks

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~2 weeks

This trial's timeline: 3 weeks for screening, Varies for treatment, and 2 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Body Weight Changes

Change in blood glucose while on empagliflozin

Number of participants with adverse effects from empagliflozin

Secondary outcome measures

Seizures

Trial Design

2Treatment groups

Experimental Treatment

Group I: Placebo / EmpagliflozinExperimental Treatment2 Interventions

Participants randomized to this arm will receive placebo daily for 2 weeks followed by 25 mg of empagliflozin daily for 2 weeks

Group II: Empagliflozin / PlaceboExperimental Treatment2 Interventions

Participants randomized to this arm will receive 25 mg of empagliflozin daily for 2 weeks followed placebo daily for 2 weeks

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Empagliflozin 25 mg

2019

Completed Phase 2

~60

Placebo

1995

Completed Phase 3

~2670

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Washington University School of MedicineLead Sponsor

1,931 Previous Clinical Trials

2,299,691 Total Patients Enrolled

1 Trials studying Epilepsy

90 Patients Enrolled for Epilepsy

Kwee L ThioPrincipal InvestigatorWashington University School of Medicine

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the total sample size for this experiment?

"Affirmative. According to the clinicaltrials.gov database, recruitment for this medical study began on August 17th 2022 and is continuing until 18 participants have been enrolled at a single site."

Answered by AI

Is the upper age limit for enrolment in this research project 75 years?

"Qualified applicants must be 18 years of age or older, with the upper limit for enrollment set at 45."

Answered by AI

Is it possible to enroll in this investigation?

"This research is seeking 18 volunteers who experience aura and are aged between 18-45. Most crucially, the eligible candidates must have one of the following epileptic conditions: focal, generalized, combined generalized and focal or an unknown type. Additionally, the epilepsy should be either drug-responsive or drug resistant."

Answered by AI

Is enrollment for this trial currently open?

"According to clinicaltrials.gov, this trial is actively sourcing participants. The initial post date was August 17th 2022 and the listing has since been updated on 8/20/2022."

Answered by AI

Recent research and studies

NeurologyJournal

Low-glycemic-index Treatment: A Liberalized Ketogenic Diet for Treatment of Intractable Epilepsy

Pfeifer, H. H., and E. A. Thiele. 2005. “Low-glycemic-index Treatment: A Liberalized Ketogenic Diet for Treatment of Intractable Epilepsy”. Neurology. Ovid Technologies (Wolters Kluwer Health). doi:10.1212/01.wnl.0000187071.24292.9e.

EpilepsiaJournal

The Ketogenic Diet in a Pill: Is This Possible?

Rho, Jong M., and Raman Sankar. 2008. “The Ketogenic Diet in a Pill: Is This Possible?”. Epilepsia. Wiley. doi:10.1111/j.1528-1167.2008.01857.x.

Nature CommunicationsJournal

SGLT2 Inhibition Modulates NLRP3 Inflammasome Activity via Ketones and Insulin in Diabetes with Cardiovascular Disease

Kim, So Ra, Sang-Guk Lee, Soo Hyun Kim, Jin Hee Kim, Eunhye Choi, Wonhee Cho, John Hoon Rim, et al.. 2020. “SGLT2 Inhibition Modulates NLRP3 Inflammasome Activity via Ketones and Insulin in Diabetes with Cardiovascular Disease”. Nature Communications. Springer Science and Business Media LLC. doi:10.1038/s41467-020-15983-6.

Annals of NeurologyJournal